# Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

> **NCT06449339** · PHASE4 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 474 (estimated)

## Conditions studied

- Portal Hypertension
- Hepatic Decompensation
- Advanced Chronic Liver Disease

## Interventions

- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT06449339
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2031-07-30
- **Final completion:** 2031-07-30
- **Target enrollment:** 474 (ESTIMATED)
- **Last updated:** 2025-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449339, "Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06449339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*